Cargando…
Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis
AIMS: Since 2005, several glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have been approved to treat people with type 2 diabetes. These agents are considered for use at the same point in the treatment paradigm as basal insulins. A comprehensive comparison of these drug classes, therefore, can...
Autores principales: | Singh, Sonal, Wright, Eugene E., Kwan, Anita Y. M., Thompson, Juliette C., Syed, Iqra A., Korol, Ellen E., Waser, Nathalie A., Yu, Maria B., Juneja, Rattan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299485/ https://www.ncbi.nlm.nih.gov/pubmed/27717130 http://dx.doi.org/10.1111/dom.12805 |
Ejemplares similares
-
Use of glucagon‐like peptide‐1 receptor agonists among individuals on basal insulin requiring treatment intensification
por: Trautmann, M. E., et al.
Publicado: (2018) -
Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
por: Mehta, Roopa, et al.
Publicado: (2022) -
The Evolution of Insulin and How it Informs Therapy and Treatment Choices
por: Hirsch, Irl B, et al.
Publicado: (2020) -
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes
por: Nomoto, Hiroshi
Publicado: (2023) -
Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
por: Berlie, Helen, et al.
Publicado: (2012)